SIRT3 and hepatocellular carcinoma: Overall, it remains unknown if sirtuin activation or inhibition is an appropriate therapeutic strategy for HCC, as targeting individual sirtuins for activation (SIRT3) and inhibition (SIRT6) may be indicated based on previous research [184,198,199].